CABA Stock Risk & Deep Value Analysis
Cabaletta Bio Inc
DVR Score
out of 10
What You Need to Know About CABA Stock
We analyzed Cabaletta Bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CABA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CABA Risk Analysis & Red Flags
What Could Go Wrong
The company's explicit 'going-concern doubt beyond Q4 2026' and the proxy request to double authorized shares signal an imminent and significant need for capital. If the subsequent financing round results in substantial dilution (e.g., 50% to 100%+ increase in outstanding shares), it could severely impair per-share value, potentially causing a dramatic stock price decline regardless of clinical progress.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
10-K filed March 23, 2026, notes 'going-concern doubt beyond Q4 2026'.
- ⚠
DEF 14A on April 10, 2026, seeks to double authorized shares to 600M, signaling likely significant dilution.
- ⚠
Ongoing negative EBITDA and cash burn, typical for clinical-stage biotech but exacerbated by funding runway concerns.
Upcoming Risk Events
- 📅
Unfavorable clinical data from ASGCT 2026 or subsequent trials
- 📅
Failure to secure adequate financing or highly dilutive financing terms
- 📅
Regulatory setbacks or delays in drug development
When to Reconsider
- 🚪
Exit if dilution in the next financing round exceeds 100% of current shares outstanding.
- 🚪
Sell if CABA-201 or rese-cel clinical data at ASGCT or subsequent readouts are materially negative or fail to meet expectations.
- 🚪
If the company fails to announce a financing solution by Q3 2026.
Unlock CABA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Cabaletta Bio holds significant 10x growth potential through its innovative precision cell therapy platform for severe autoimmune diseases, with CABA-201 showing promising early data and addressing vast unmet needs. The recent manufacturing deal and upcoming clinical presentations are strong operational positives. However, this potential is currently overshadowed by critical 'going-concern' financial risk, requiring immediate resolution through a financing round that will likely entail substantial share dilution. Investment hinges on successful clinical progression and the company's ability to secure funding without overly diluting shareholders.
Is CABA Stock Undervalued?
Unlock the full AI analysis for CABA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CABA Price Targets & Strategy
12-Month Target
$11.00
Bull Case
$18.00
Bear Case
$1.50
Valuation Basis
Based on 0.5x projected peak sales potential of rese-cel in early indications, discounted for clinical risk and an estimated 50-75% share dilution over 12 months.
Entry Strategy
Dollar-cost average between $2.50-$3.00, with a strong focus on news regarding financing and clinical data. Optimal entry after clarity on dilution terms.
Exit Strategy
Take partial profits at $7.00 and $11.00. Re-evaluate at $18.00. Stop-loss at $1.80 if financial news deteriorates further or clinical data disappoints.
Portfolio Allocation
3% for aggressive risk tolerance, only for high-conviction investors willing to stomach significant volatility and potential capital loss.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is CABA Financially Healthy?
Valuation
P/E Ratio
-1.40
Price/Book
2.90
Profitability
Return on Equity
-121.73%
EPS
$-2.28
Balance Sheet
Current Ratio
2.77
Quick Ratio
2.66
Debt/Equity
0.21
Cash Flow
Operating Cash Flow
-$131.00M
Free Cash Flow
-$132.30M
EBITDA
-$170.60M
Other
Beta (Volatility)
3.22
Does CABA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat, primarily based on proprietary technology and clinical differentiation, is currently expanding as CABA generates promising clinical data. Its durability will hinge on successful late-stage trials, regulatory approvals, and the ability to scale manufacturing and commercialization ahead of competitors.
Moat Erosion Risks
- •Clinical trial failures or safety concerns that undermine the platform's efficacy.
- •Competitors developing superior or faster-to-market therapies.
- •Challenges in manufacturing scale-up or cost-effectiveness relative to existing treatments.
CABA Competitive Moat Analysis
Sign up to see competitive advantages
CABA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral/Cautious. While clinical progress generates some bullish sentiment, the significant financial concerns likely foster caution among retail investors.
Institutional Sentiment
Mixed. Analyst consensus is Moderate Buy with a $17.00 target, but Wall Street Zen downgraded to Hold→Sell, reflecting increased skepticism due to financial uncertainty.
Insider Activity (Form 4)
Insiders purchased 127,668 shares over the last 90 days, now owning 11.25% of the company. No specific Form 4 details (names, values) available in the research brief.
Options Flow
Normal options activity (no specific unusual activity flagged in the research).
Earnings Intelligence
Next Earnings
2026-05-14 (Q1 2026 estimate, actual report May 21, 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Q4 2025 EPS beat estimates, indicating some operational efficiency. Stock price reaction to earnings is typically driven by clinical updates and cash position for pre-revenue biotechs.
Key Metrics to Watch
Competitive Position
Top Competitor
Bristol Myers Squibb (BMS)
Market Share Trend
N/A (pre-commercial, developing novel therapies).
Valuation vs Peers
As a clinical-stage, pre-revenue biotech, CABA's valuation is highly speculative and not directly comparable to commercial-stage peers on traditional metrics like P/E or P/S. It trades at a significant discount to its potential peak sales given the early stage and high risk.
Competitive Advantages
- •Proprietary cell therapy platform for autoimmune diseases, specifically targeting B-cell mediated autoimmunity.
- •Early-mover advantage in precision CAR T for autoimmune conditions like lupus and systemic sclerosis.
- •Potential for first-in-class therapies addressing high unmet medical needs.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive CABA Stock Higher?
Near-Term (0-6 months)
- •New rese-cel data presentation at ASGCT 2026 (May 11-15)
- •Q1 2026 Earnings (Expected May 14, 2026)
- •Resolution of 'going concern' through financing announcement (likely Q2/Q3 2026)
Medium-Term (6-18 months)
- •Further Phase 1/2 clinical data readouts for CABA-201
- •Advancement of manufacturing partnership with Cellares
- •Potential strategic partnerships or collaborations
Long-Term (18+ months)
- •Initiation of pivotal clinical trials for lead assets
- •Regulatory filings and potential market approval for rese-cel or CABA-201
- •Expansion of pipeline into additional autoimmune indications
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for CABA?
- ✓
Positive clinical data readouts for CABA-201 and rese-cel, particularly on efficacy and safety.
- ✓
Terms of the next financing round: amount raised, share price, and resulting dilution percentage.
- ✓
Updates on cash runway and progress towards commercialization readiness.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Cabaletta Bio Inc Makes Money
Cabaletta Bio is a clinical-stage biotechnology company that does not currently generate revenue. Its business model revolves around the discovery, development, and eventual commercialization of precision cell therapies for patients with severe autoimmune diseases. The company is investing heavily in research and development, particularly in advancing its lead product candidates like CABA-201 and rese-cel through various phases of clinical trials. Success in this model depends entirely on achieving positive clinical outcomes, securing regulatory approvals, and then successfully manufacturing and marketing these innovative therapies to patients, at which point product sales would become its primary revenue stream.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Cabaletta Bio Inc (CABA)?
As of May 3, 2026, Cabaletta Bio Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Cabaletta Bio Inc?
Cabaletta Bio Inc's market capitalization is approximately $327.3M..
What is the risk level for CABA stock?
Our analysis rates Cabaletta Bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CABA?
Cabaletta Bio Inc currently has a price-to-earnings (P/E) ratio of -1.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the CABA DVR analysis updated?
Our AI-powered analysis of Cabaletta Bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CABA (Cabaletta Bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.